Abstract 188P
Background
Due to its complex pathophysiology, several comorbidities have to be taken in count in clinical decision-making process for hepatocellular carcinoma (HCC) patients. The aim of the present work was to investigate the potential prognostic role of metformin, aspirin, statins and insulin use in a cohort of advanced HCC patients who received Lenvatinib or atezolizumab plus bevacizumab as first- line treatment.
Methods
The population included HCC patients who received Atezolizumab plus Bevacizumab or Lenvatinib as first- line therapy. Univariate and multivariate analyses were performed by Cox proportional hazard to assess possible association between patients’ baseline characteristics and survival outcomes.
Results
730 patients with HCC were included in the analysis: 430 received Lenvatinib and 300 received Atezolizumab plus Bevacizumab. In both the treatment arms, no statistically differences in terms of OS and PFS were highlighted in patients who make chronic use of statin, aspirin or insulin compared to those who do not. In the Atezolizumab plus Bevacizumab arm, 50 (16.5%) patients were recorded to chronically use metformin. Patients in metformin group showed significantly shorter OS compared to patients in no-metformin group [respectively, 14.9 months (95% CI 6.4-16.3) vs. 19.7 (95% CI 16.0-30.4); HR 1.9 (95% CI 1.1-3.2) p = 0.0248], as confirmed in multivariate analysis (HR 1.9; 95% CI, 1.1-3.1; p=0.0163). Moreover, patients in metformin group had significantly shorter PFS compared to patients in no-metformin group [respectively, 4.5 months (95% CI 2.9-14.2) vs. 5.8 (95% CI 4.1-34.0); HR 1.6 (95% CI 1.0-2.6) p = 0.0212], as confirmed in multivariate analysis (HR 1.7; 95% CI, 1.1-2.7; p=0.0147).No statistically significant differences in terms of both OS and PFS were found between patients in metformin group and patients in no-metformin group in Lenvatinib arm.
Conclusions
The present study reports the first analysis focused on the role of metformin in a large double cohort of patients affected by advanced HCC who received Lenvatinib or Atezolizumab plus Bevacizumab, thus showing a negative prognostic role of metformin use in the Atezolizumab plus Bevacizumab group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract